News | May 01, 2025
Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Subsidiary has received one inspectional observation in Form 483
Alembic Pharmaceuticals commissions new facility at Pithampur
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
ekincare has raised a total funding of $22M since 2015 till date
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
The inspection concluded with 6 observations and none of them were related to Data Integrity
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Subscribe To Our Newsletter & Stay Updated
